Linkedin Youtube
Launch Digital Edition

Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

Qiagen, Incyte to develop CDx for patients with myeloproliferative neoplasms

September 2025—Qiagen is collaborating with Incyte to develop a novel diagnostic panel to support Incyte’s portfolio of investigational therapies, including Incyte’s monoclonal antibody INCA033989, for patients with myeloproliferative neoplasms. Under the terms of the master collaboration agreement, Qiagen will develop a multi­modal panel using next-generation sequencing technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the Illumina NextSeq 550Dx.

Illumina launches TruSight Oncology 500 v2 research assay

September 2025—Illumina has launched TruSight Oncology 500 version 2, the next generation of the company’s flagship pancancer next-generation sequencing assay that enables in-house comprehensive genomic profiling from formalin-fixed, paraffin-embedded tissue for oncology research. A key enhancement of the new assay is fully integrated homologous recombination deficiency analysis included for every sample, powered by a gold-standard genomic instability scoring algorithm licensed from Myriad Genetics. Other updates include more sensitive variant calling and improved coverage of difficult genomic regions. The new kit has 50 percent less packaging and 70 percent fewer tubes.

SehaMed, New Day Dx to launch ColoHealth in the Middle East

September 2025—SehaMed Global (Bristol, England) announced a strategic distribution agreement with New Day Diagnostics of Knoxville, Tenn., to bring ColoHealth, an FDA-approved blood test for the early detection of colorectal cancer, to patients in Saudi Arabia, the United Arab Emirates, and other countries in the Middle East. Under the terms of the agreement, SehaMed will leverage its network of distributors across the Gulf Cooperation Council to introduce ColoHealth.

Vizgen, Hamamatsu partner to streamline spatial biology workflows

August 2025—Vizgen and Hamamatsu Photonics have entered a strategic partnership that integrates Hamamatsu’s MoxiePlex multiplex immunofluorescence imaging system with Vizgen’s reagent and assay portfolio. The companies plan to combine their expertise through validated In­SituPlex panels, coupled with MoxiePlex, as an integrated multiplexed proteomic biomarker offering capable of multisite deployments for translational and clinical research applications.

IDT unveils infectious disease research solutions

August 2025—Integrated DNA Technologies has unveiled its PrimeTime influenza kit and PrimeTime research pathogen panels. The influenza kit is a qPCR solution designed to amplify common influenza strains and targets influenza A, influenza A (H5N1), influenza B, and RNase. It includes an internal control for sample quality assessment, a premixed primer and probe set, PrimeTime 4x Broad-Range Master Mix, and direct amplification enhancer.

MRC Holland assay for Peutz-Jeghers gains EU IVDR certification

August 2025—MRC Holland announced that its Salsa MLPA Probemix P101 STK11 assay for the detection of Peutz-Jeghers syndrome received the CE mark for in vitro diagnostic use under IVDR regulation EU 2017/746. The probe mix detects copy number variations in the STK11 gene and has been updated with two improved and two newly added denaturation control probes that facilitate the detection of denaturation issues with exceptional sensitivity, according to a company press statement.

SSI Diagnostica acquires Gulf Coast Scientific

August 2025—SSI Diagnostica Group is acquiring Gulf Coast Scientific (Oldsmar, Fla.), which specializes in the development of urea breath testing for Helicobacter pylori, to further strengthen its gastrointestinal disease testing portfolio. SSI Diagnostica, headquartered in Denmark, acquired CTK Biotech (Poway, Calif.) in 2020 and TechLab (Blacksburg, Va.) in 2022. Jointly the group will have a total revenue of approximately $125 million.

Waters acquires Halo Labs

August 2025—Waters Corp. announced it has acquired Halo Labs. Halo Labs’ Aura platform, which features a highly differentiated technology that performs full spectrum particle analysis, is complementary to the Waters light-scattering detection solutions from its Wyatt Technology portfolio. The subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T cells for cell therapy. By acquiring Halo Labs, Waters said it will be able to integrate the emerging technology into new and existing large molecule development and QA/QC.

Randox unveils Evidence RABTA

August 2025—Randox has launched the Evidence RABTA (random access biochip technology analyzer), capable of processing up to 60 samples per hour and delivering up to 2,640 test results per hour. The analyzer offers seamless random access capabilities, allows users to assign samples as priority, and uses single-use tips for aspiration and dispensing. The time to first result is 36 minutes, with up to 44 results per sample. Walkaway time is up to 2.5 hours.

Revvity launches IDS i20 platform from Euroimmun

August 2025—Revvity announced the launch of its IDS i20 analytical random access platform from Euroimmun, enabling full automation of chemiluminescence immunoassays. The CE-marked and FDA-listed IDS i20 allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. The specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer’s disease, and therapeutic drug monitoring. The instrument can process up to 140 tests per hour and features continuous loading of samples and reagents as well as integrated cooling of ready-to-use reagent cartridges. It is for in vitro diagnostic use.

MARKETPLACE

TRENDING